• DOT1L Inhibition Enhances Immunomodulatory Drug Response in

  2026-05-07

  This study demonstrates that inhibition of DOT1L reprograms innate immune signaling in multiple myeloma (MM), leading to potentiation of immunomodulatory drug (IMiD) efficacy. By dissecting the mechanistic interplay between DOT1L, interferon signaling, and DNA damage pathways, the research identifies DOT1L as a critical epigenetic target for overcoming therapeutic resistance in MM.

• Chemically Modified SOD2 mRNA-LNPs Mitigate Renal IRI in Mic

  2026-05-06

  This study demonstrates that lipid nanoparticle (LNP)-delivered, chemically modified SOD2 mRNA can significantly reduce renal injury following ischemia-reperfusion in mice. By leveraging optimized mRNA design and delivery, the research offers mechanistic and translational insight into mRNA therapeutics for acute kidney injury.

• Erastin as a Ferroptosis Inducer: Mechanisms, Protocols, and

  2026-05-06

  Explore how Erastin, a potent ferroptosis inducer, advances cancer biology research and immunotherapy. This article uniquely details the immunological synergy and protocol nuances that set Erastin apart.

• Mechanical Forces Activate GABAB Receptor Independent of GAB

  2026-05-05

  This study uncovers a novel, ligand-independent mechanism for GABAB receptor activation, showing that mechanical forces such as shear stress directly induce receptor signaling via integrin-GB1 interactions. These insights expand our understanding of mechanotransduction in the central nervous system and highlight new research avenues for cytoskeletal and signaling studies.

• Bestatin (Ubenimex): Advanced Workflows for Aminopeptidase I

  2026-05-05

  Bestatin (Ubenimex) from APExBIO empowers researchers to precisely measure and manipulate aminopeptidase activity in cancer and multidrug resistance studies. This guide delivers actionable protocol parameters, troubleshooting strategies, and a translational bridge from angiogenesis research to practical bench workflows.

• Dissecting Drug Responses: Growth Inhibition vs. Cell Death

  2026-05-04

  Schwartz’s dissertation advances cancer drug evaluation by distinguishing between drug-induced growth inhibition and cell death using in vitro methods. This nuanced approach uncovers the distinct timing and proportion of these effects, enabling more precise mechanistic studies and translational insights for anti-cancer drug development.

• Strategic Application of SAG in Translational Hedgehog Pathw

  2026-05-04

  This article provides a mechanistic and strategic framework for deploying Smoothened Agonist (SAG) in translational Hedgehog pathway research. We synthesize evidence from disease models, competitive antagonism, and recent literature—including medulloblastoma studies—to guide stem cell, neuroregeneration, and oncology investigators. Protocol recommendations, experimental pitfalls, and a forward-looking translational outlook are provided for maximum impact.

• LDN-193189: Mechanistic Insights and Assay Design for BMP Pa

  2026-05-03

  Explore how LDN-193189, a selective ALK inhibitor, elevates BMP signaling research through rigorous mechanistic understanding and nuanced assay optimization. This article uniquely bridges molecular mechanisms with practical protocol guidance for advanced epithelial and stem cell studies.

• Spiroplasma eriocheiris Entry into Drosophila S2 Cells: Endo

  2026-05-02

  This study systematically elucidates the cellular entry mechanisms of Spiroplasma eriocheiris in Drosophila Schneider 2 (S2) cells, identifying reliance on clathrin-mediated endocytosis and macropinocytosis. The findings provide a refined invertebrate model for understanding Spiroplasma infection biology, guiding research on host-pathogen interactions and potential intervention strategies.

• Lumiracoxib (SKU B1458): Selective COX-2 Inhibition in Advan

  2026-05-01

  This article provides biomedical researchers and lab technicians with scenario-driven, evidence-backed guidance on using Lumiracoxib (SKU B1458) for selective COX-2 inhibition in cell viability and tissue injury models. We address real laboratory challenges—from assay optimization to vendor reliability—grounding each recommendation in recent literature and validated product specifications. Lumiracoxib’s potency, selectivity, and documented performance offer a robust solution for reproducible, high-sensitivity experiments.

• ML-7 Hydrochloride: Applied MLCK Inhibition in Cardiac & Can

  2026-05-01

  ML-7 hydrochloride stands as a benchmark myosin light chain kinase inhibitor, delivering reproducible results in both cardiovascular and cancer research. This article dissects practical workflows, key innovations, and troubleshooting strategies that maximize the utility of ML-7 hydrochloride, bridging evidence from recent breast cancer invasion studies to advanced ischemia/reperfusion injury models.

• Nitrocefin: The Gold Standard Chromogenic Cephalosporin Subs

  2026-04-30

  Nitrocefin empowers rapid, visual, and quantitative detection of β-lactamase activity, uniquely enabling resistance profiling and inhibitor screening even in challenging clinical isolates. This guide translates cutting-edge research into practical protocols and troubleshooting insights for maximizing assay reliability and sensitivity.

• HyperFluor 488 Goat Anti-Mouse IgG: Boosting Immunofluoresce

  2026-04-30

  Harness the HyperFluor 488 Goat Anti-Mouse IgG antibody for robust, high-sensitivity detection in immunofluorescence, flow cytometry, and western blot assays. Real-world workflows and troubleshooting strategies reveal how this APExBIO reagent streamlines endothelial injury research and optimizes results across advanced immunoassay platforms.

• Capecitabine in Preclinical Oncology: Applied Workflows & Ti

  2026-04-29

  Capecitabine’s tumor-selective activation and robust apoptosis induction via Fas-dependent pathways make it a premier tool for advanced preclinical oncology research. Explore optimized workflows, troubleshooting strategies, and key insights from assembloid models for maximizing assay predictivity and translational relevance.

• AM251: Potent CB1 Receptor Antagonist for Cannabinoid Resear

  2026-04-29

  AM251 is a highly selective and potent CB1 receptor antagonist, central to cannabinoid receptor research and neuropharmacology. With nanomolar affinity and validated effects in both in vitro and in vivo models, AM251 offers robust tools for the study of endocannabinoid signaling, metabolic disorders, and cell regulation.

764 records 19/51 page Previous Next First page 上5页 1617181920 下5页 Last page